← Leaderboards
Mark Daniel Hicar
Vanderbilt University
$2,686,211
Attributed
$2,686,211
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $391.9K · FY2009–25$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,686,211 · 3
By mechanism
R01$1,956,865 · 1
K08$638,820 · 1
T35$90,526 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Derya Unutmaz$17,997,547
- Nancy J Olsen$6,548,556
- Roy A. Jensen$20,860,843
- James W Thomas$1,648,697
- Charles K Singleton$885,541
Others in their field
Top investigators on “Play”
- Lawrence Corey · Fred Hutchinson Cancer Center$428,785,907
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Jeffrey P Krischer · University Of South Florida$191,869,794
- Constance Ann Benson · University Of California, San Diego$187,132,366
Research focus
PlayB-LymphocytesInfectionVaccine DesignAntibodiesNeutralizing AntibodyVaccinesHiv InfectionsMutateSurface Plasmon ResonanceEpitopesViralSpecificityResponseEnv Gene ProductsBaseEnzyme-Linked Immunosorbent AssayDesignAcidsAffectCell LineAntigen TargetingAntigensClinic
Grant awards (11)
Training the Next Generation of Clinician Scientist$90,526
T35 · FY2025 · AI · contact PI
The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infection$390,782
R01 · FY2020 · AI · contact PI
The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infection$391,089
R01 · FY2019 · AI · contact PI
The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infection$391,389
R01 · FY2018 · AI · contact PI
The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infection$391,667
R01 · FY2017 · AI · contact PI
The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infection$391,938
R01 · FY2016 · AI · contact PI
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)$127,764
K08 · FY2013 · AI · contact PI
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)$127,764
K08 · FY2012 · AI · contact PI
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)$127,764
K08 · FY2011 · AI · contact PI
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)$127,764
K08 · FY2010 · AI · contact PI
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)$127,764
K08 · FY2009 · AI · contact PI